Cargando…
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
The epothilone B analog, ixabepilone, demonstrates low susceptibility to drug resistance mechanisms and has demonstrated clinically meaningful efficacy in patients refractory to other chemotherapeutic options. Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955910/ https://www.ncbi.nlm.nih.gov/pubmed/20886213 http://dx.doi.org/10.1007/s00280-010-1467-x |